What do cardiologists think of PCSK9 inhibitors?

The case for PCSK9 inhibitors is strong following the American College of Cardiology's 67th annual symposium in Orlando, Florida, but some physicians remain wary of the medication, citing gaps in clinical evidence and questioning if cardiology is ready for the widespread distribution of such pricey drugs. read more

Mayo Clinic cardiologists Jeffrey Geske, Scott Wright, and Stephen Kopecky discuss the brave new world of PCSK9 inhibitors. Mayo Clinic cardiologists Jeffrey Geske, Scott Wright, and Stephen Kopecky discuss the brave new world of PCSK9 inhibitors. read more

Cardiologists have never been faced with a situation like this," said DeMaria, who noted that the prices quoted for the PCSK9 drugs were similar to the costs of cancer drugs but with an important difference: "these drugs are forever. read more

From Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. the team from UCSF looked at the current cost of PCSK9 inhibitors at $14,500 / patient-year and compared the benefit of the inhibitors vs. the current standard of care. read more